Pfizer and its German partner, BionTech, request an extension of emergency use of their vaccine to adolescents | latest news


Pfizer and its German partner Biontech said on Friday that they have asked US regulatory agencies to extend the emergency use of their COVID-19 vaccine for teens between 12 and 15 years old.

In March, the two drug companies said that clinical trials had demonstrated the vaccine was safe and helped generate strong antibodies in adolescents between the ages of 12 and 15.

And still the big question that pharmaceutical companies are trying to answer is whether vaccines against Covid-19 are effective and safe when used to vaccinate children.

Experts say that vaccinating children and young people is a crucial step towards achieving what is known as “herd immunity” and containing the epidemic.

The Pfizer Bionic vaccine, consisting of two doses per person, is already approved for use by those aged 16 years and over.


Please enter your comment!
Please enter your name here